

**CLAIMS**

What is claimed is:

1. A topical testosterone formulation comprising:  
a modified poloxamer lecithin organogel carrier having admixed therein,  
5 an arginine ingredient in an amount of from about 0.1 to about 20% w/w, and a  
tocopherol ingredient in an amount of from about 0.1 to about 20% w/w; and  
a therapeutically effective amount of micronized testosterone.
2. The formulation of claim 1, wherein the amount of micronized  
10 testosterone is from about 0.5% w/w to about 25% w/w of the formulation.
3. The formulation of claim 1, wherein the amount of micronized  
testosterone is from about 5% w/w to about 10% w/w of the formulation.
4. The formulation of claim 1, wherein the arginine ingredient is in a salt  
15 form.
5. The formulation of claim 4, wherein the arginine ingredient is L-arginine  
monochloride.  
20
6. The formulation of claim 1, wherein the amount of arginine ingredient is  
from about 5% w/w to about 10% w/w of the formulation.
7. The formulation of claim 1, wherein the tocopherol ingredient comprises  
25 alpha tocopherol.
8. The formulation of claim 1, wherein the tocopherol ingredient comprises  
gamma tocopherol.
9. The formulation of claim 1, wherein the amount of the tocopherol  
30 ingredient is from about 5% w/w to about 10% w/w of the formulation.
10. The formulation of claim 1, further comprising an effective amount of  
dehydroepiandrosterone (DHEA).

11. The formulation of claim 10, wherein the DHEA comprises dehydroepiandrosterone sulfate (DHEAS).

5 12. The formulation of claim 10, wherein the amount of DHEA is about from about 1% w/w to about 20% w/w of the formulation.

13. The formulation of claim 1, further comprising an effective amount of melatonin.

10 14. The formulation of claim 13, wherein the amount of melatonin is from about 1% w/w to about 20% w/w of the formulation.

15 15. The formulation of claim 1 further comprising an effective amount of progesterone.

16. The formulation of claim 15, wherein the amount of progesterone is from about 1% w/w to about 20% w/w of the formulation.

20 17. The formulation of claim 1 wherein further comprising an effective amount of oxytocin.

18. The formulation of claim 17, wherein the amount of oxytocin is from about 1% w/w to about 20% w/w of the formulation.

25 19. The formulation of claim 1 wherein the amount of testosterone is from about 5% w/w to about 10% w/w, the amount of tocopherol is from about 5% w/w to about 10% w/w, and the amount of arginine is from about 5-10% of the formulation.

30 20. A topical testosterone formulation comprising:  
from about 10% w/w to about 20% w/w natural testosterone having a particulate size of less than about 20 micrometers;  
from about 5% w/w to about 10% w/w alpha tocopherol;  
35 from about 5% w/w to about 10% w/w L-arginine monochloride;

from about 5% w/w to about 10% w/w DHEA;  
from about 5% w/w to about 10% w/w melatonin; and  
from about 5% w/w to about 10% w/w oxytocin; admixed into a modified  
poloxamer lecithin organogel carrier.